Absci(ABSI.US)

Last Updated 19:00:00 ET
longbridge loading

HC Wainwright Has Optimistic Outlook of Absci Q3 Earnings

Market Beat·
US
ABSI
+5.94%
Market Beat·
US
ABSI
+5.94%

AbSci (ABSI) Receives a Rating Update from a Top Analyst

Tip Ranks·
US
ABSI
+5.94%
US
LABU
+10.93%
US
PBE
+1.37%
Tip Ranks·
US
ABSI
+5.94%
US
LABU
+10.93%
US
PBE
+1.37%

AbSci Price Target Raised to $11 as Analyst Reiterates Buy on Promising PRLR Pipeline and ABS-201 Data

Tip Ranks·
US
ABSI
+5.94%
US
SBIO
+3.67%
US
PBE
+1.37%
Tip Ranks·
US
ABSI
+5.94%
US
SBIO
+3.67%
US
PBE
+1.37%

Absci Corp. Charts High-Stakes Path With ABS-201

Tip Ranks·
US
ABSI
+5.94%
US
IBBQ
+2.21%
US
BBH
+0.68%
Tip Ranks·
US
ABSI
+5.94%
US
IBBQ
+2.21%
US
BBH
+0.68%

12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga_article·
US
INM
+6.25%
US
AMLX
+4.20%
US
SRTS
-1.82%
benzinga_article·
US
INM
+6.25%
US
AMLX
+4.20%
US
SRTS
-1.82%

Absci shares are trading lower after the company reported mixed Q1 financial results.

benzinga_article·
US
ABSI
+5.94%
benzinga_article·
US
ABSI
+5.94%

Brendan Smith Reiterates Buy on AbSci, Citing Emerging PRLR Franchise and Multiple Upcoming Clinical Catalysts

Tip Ranks·
US
ABSI
+5.94%
US
XBI
+3.62%
US
IBBQ
+2.21%
Tip Ranks·
US
ABSI
+5.94%
US
XBI
+3.62%
US
IBBQ
+2.21%

Absci | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 215 K

Earnings Watch·
US
ABSI
+5.94%
Earnings Watch·
US
ABSI
+5.94%

Absci | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 215 K

Earnings Watch·
US
ABSI
+5.94%
Earnings Watch·
US
ABSI
+5.94%
© 2026 Longbridge｜Disclaimer